Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice

DPP-4 inhibitors (DPP-4i) and sulphonylureas remain the most widely prescribed add-on treatments after metformin. However, there is limited evidence from clinical practice comparing major adverse cardiovascular events (MACE) in patients prescribed these treatments, particularly among those without p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazo-Alvarez, Juan Carlos, Pal, Kingshuk, Pham, Tra My, Nazareth, Irwin, Petersen, Irene, Sharma, Manuj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668905/
https://www.ncbi.nlm.nih.gov/pubmed/34903733
http://dx.doi.org/10.1038/s41598-021-02670-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668905/
https://www.ncbi.nlm.nih.gov/pubmed/34903733
http://dx.doi.org/10.1038/s41598-021-02670-9

Ejemplares similares